secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115317
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q3 2024: revenue $19.0M (+26% YoY), net loss $10.4M; reaffirms FY2024 guidance
--------------------------------------------------------------------------------

- Revenue $19.0M, +26% YoY; OviTex unit sales +39%, OviTex PRS +44% YoY.
- Net loss $10.4M vs $11.0M loss in Q3 2023; operating loss $9.4M vs $10.2M.
- Gross margin 68% vs 69% YoY due to higher excess/obsolete inventory charge.
- Closed public offering yielding ~$46M gross proceeds; cash $17.3M at Sept 30.
- Expects $5M-$10M reduction in 2025 operating expenses from H1 2024 annualized; reiterates FY2024 revenue guidance $74.5M-$76.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924115317/0001104659-24-115317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924115317/tm2427737d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer